HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fratta, P. Articles by Askanas, V. Search for Related Content PubMed PubMed Citation Articles by Fratta, P. Articles by Askanas, V. Related Collections Muscle disease

Mutant ubiquitin UBB⁺¹ is accumulated in sporadic inclusion-body myositis muscle fibers

From the USC Neuromuscular Center (Drs. Fratta, Engel, Vattemi, and Askanas), Department of Neurology, University of Southern California Keck School of Medicine, Good Samaritan Hospital, Los Angeles, CA; and Netherlands Institute for Brain Research (Drs. Van Leeuwen and Hol), Research Group Molecular Misreading, Amsterdam, The Netherlands.

Address correspondence and reprint requests to Dr. Valerie Askanas, USC Neuromuscular Center, Good Samaritan Hospital, 637 South Lucas Avenue, Los Angeles, CA 90017-1912; e-mail: askanas{at}hsc.usc.edu

Mutant ubiquitin (UBB⁺¹), a product of "molecular misreading," is toxic to cells because its ubiquitinated form inhibits the proteasome, contributing to accumulation of misfolded proteins and their ensuing toxicity. The authors demonstrate in 10 sporadic inclusion body myositis (s-IBM) muscle biopsies that UBB⁺¹ is accumulated in aggregates containing amyloid-ß and phosphorylated-tau. In s-IBM, UBB⁺¹ may be pathogenic by inhibiting proteasome, thereby promoting accumulation of cytotoxic misfolded amyloid-ß and phosphorylated-tau.

Received February 18, 2004. Accepted in final form May 14, 2004.

This article has been cited by other articles:

				L. G. G. C. Verhoef, C. Heinen, A. Selivanova, E. F. Halff, F. A. Salomons, and N. P. Dantuma Minimal length requirement for proteasomal degradation of ubiquitin-dependent substrates FASEB J, January 1, 2009; 23(1): 123 - 133. [Abstract] [Full Text] [PDF]

				P. van Tijn, F. M. S. de Vrij, K. G. Schuurman, N. P. Dantuma, D. F. Fischer, F. W. van Leeuwen, and E. M. Hol Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease J. Cell Sci., May 1, 2007; 120(9): 1615 - 1623. [Abstract] [Full Text] [PDF]

				C. E. Finch A perspective on sporadic inclusion-body myositis: The role of aging and inflammatory processes Neurology, January 24, 2006; 66(1_suppl_1): S1 - S6. [Abstract] [Full Text] [PDF]

				V. Askanas and W. K. Engel Inclusion-body myositis: A myodegenerative conformational disorder associated with A{beta}, protein misfolding, and proteasome inhibition Neurology, January 24, 2006; 66(1_suppl_1): S39 - S48. [Abstract] [Full Text] [PDF]

				F. W. van Leeuwen, P. van Tijn, M.A.F. Sonnemans, B. Hobo, D. M.A. Mann, C. Van Broeckhoven, S. Kumar-Singh, P. Cras, G. Leuba, A. Savioz, et al. Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies Neurology, January 24, 2006; 66(1_suppl_1): S86 - S92. [Abstract] [Full Text] [PDF]

				P. Fratta, W. K. Engel, J. McFerrin, K. J.A. Davies, S. W. Lin, and V. Askanas Proteasome Inhibition and Aggresome Formation in Sporadic Inclusion-Body Myositis and in Amyloid-{beta} Precursor Protein-Overexpressing Cultured Human Muscle Fibers Am. J. Pathol., August 1, 2005; 167(2): 517 - 526. [Abstract] [Full Text] [PDF]